Paige Britt

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.